Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Lurbinectedin Displays Superior Risk/Benefit Ratio Over Topotecan in SCLC

February 20th 2024

Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.

RATIONALE-315 Data Support Perioperative Tislelizumab Plus Chemo in Resectable NSCLC

February 20th 2024

Neoadjuvant tislelizumab plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab demonstrated efficacy in resectable non–small cell lung cancer.

UV1 Receives Orphan Drug Designation From EMA in Mesothelioma

February 19th 2024

The European Medicines Agency has granted orphan drug designation to UV1 in patients with mesothelioma.

FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC

February 19th 2024

A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.

Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC

February 19th 2024

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

Reflex Molecular Testing May Enhance Targeted Therapy Benefit in Early-Stage Lung Cancer

February 19th 2024

Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.

Dr Jänne on the FDA Approval of Osimertinib Plus Chemotherapy in EGFR+ mNSCLC

February 16th 2024

Pasi A. Jänne, MD, PhD, discusses the FDA approval of osimertinib plus chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC.

FDA Approves Osimertinib Plus Chemo for EGFR-Mutated NSCLC

February 16th 2024

The FDA has approved osimertinib (Tagrisso) plus chemotherapy for use in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations

February 15th 2024

The FDA has granted approval to tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Breaking Boundaries: Advancements and Challenges in Treatment with ADCs in NSCLC

February 15th 2024

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

Unlocking the Potential: The Evolution of ADCs in HER2+ NSCLC

February 14th 2024

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

FDA Grants Priority Review to Repotrectinib for NTRK+ Solid Tumors

February 14th 2024

Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.

Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLC

February 13th 2024

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

Future Perspectives in ADCs for Treating Advanced NSCLC

February 12th 2024

Dr. Shirish Gadgeel discusses the activity of antibody drug conjugates against brain metastases in non-small cell lung cancer based on emerging data, suggesting superiority over chemotherapy.

Dr Sabari on the Potential Role for Patritumab Deruxtecan in NSCLC

February 9th 2024

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

European Approval Sought for Frontline Amivantamab Plus Lazertinib in EGFR+ NSCLC

February 9th 2024

The EMA is evaluating a Type II extension of indication application for the approval of first-line amivantamab plus lazertinib in EGFR-mutated NSCLC.

Patritumab Deruxtecan (HER3-DXd) in Patients with EGFR Mutation-Positive Advanced NSCLC

February 9th 2024

Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization

February 7th 2024

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?

February 7th 2024

Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.

EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management

February 7th 2024

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.